• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>The journal of clinical psychiatry >Dr Joksovic and colleagues reply
【24h】

Dr Joksovic and colleagues reply

机译：Joksovic博士及其同事回覆

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Most clinical trials of ketamine have been conducted in adults with treatment-resistant MDD, though some trials have been conducted in patients with bipolar depression.9"11 Studies generally included patients with comorbid anxiety disorders and excluded those with recent polysubstance dependence histories. Route of administration has been overwhelminglyJV, and ketamine dosing has ranged from 0.25 to 0.5 mg/kg for 40-60 minutes. A detailed review by Aan Het Rot and colleagues1 tabulated response rates in controlled trials and found that at 24 hours postinfusion, 25%-71% of patients demonstrated a sustained ketamine response—defined as a > 50% reduction in scores on at least 1 measure of depression; at 72 hours, 14%-50% of patients had maintained response. A recent study (ClinicalTrials.gov identifier: NCT00768430) was conducted to address concerns regarding effective blinding and found that remission rates to ketamine were superior to those for the active comparator midazolam. The study demonstrated that 35% of patients given ketamine showed signs of remission after both 1 and 7 days, compared to 8% and 18% for midazolam at the same time measurements.
机译：氯胺酮的大多数临床试验都是在具有治疗耐受性MDD的成人中进行的，尽管有些试验是在双相抑郁症患者中进行的。9“ 11研究通常包括患有合并症的焦虑症患者，而排除了近期有多物质依赖病史的患者。合资企业已经大量使用，氯胺酮的剂量范围为40至60分钟，剂量范围为0.25至0.5 mg / kg。Aan Het Rot及其同事1的详细评论在对照试验中列出了缓解率，发现在输注后24小时，有25％-71 ％的患者表现出持续的氯胺酮反应-定义为至少1次抑郁测量的得分降低> 50％;在72小时时，有14％-50％的患者保持了反应。最近的研究（ClinicalTrials.gov标识符： NCT00768430）旨在解决有关有效致盲的问题，发现氯胺酮的缓解率优于活性比较剂咪达唑仑。结果表明，服用氯胺酮的患者中有35％的患者在1天和7天后均显示出缓解的迹象，而咪达唑仑在同一时间的测量中分别为8％和18％。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号